

## List of Tables

Table no.	Legend	Page no.
1.1	Commonly used TM/CAM therapies and therapeutic techniques	4
1.2	Key needs in ensuring the safety, efficacy and quality of TM/CAM	12
1.3	Framework for inclusion of TM/CAM as therapeutic system	13
1.4	Current therapies used in asthma	22
1.5	Herbs used to treat asthma by culture	26
1.6	Example of commonly consumed herbal drugs for CVD and their adverse effect	30
2.1	Taxonomy of <i>Leonotis nepetaefolia</i>	32
2.2	Taxonomy classification of <i>Oxalis corniculata</i>	35
3.1	Chromatographic parameters for TLC profile of extracts	44
4.1	Proximate analysis of <i>L. nepetaefolia</i>	72
4.2	Successive extract profile of <i>L. nepetaefolia</i>	73
4.3	Phytochemical screening of successive extracts of LN leaves	73
4.4	Phytochemical screening of successive extracts of LN roots	74
4.5	TLC Profile of successive extracts of <i>Leonotis nepetaefolia</i> leaves	74
4.6	TLC Profile of successive extracts of <i>Leonotis nepetaefolia</i> root	75
4.7	Secondary metabolites <i>Leonotis nepetaefolia</i> leaves	75
4.8	Secondary metabolites <i>Leonotis nepetaefolia</i> roots	76
4.9	Validation parameters for quantification of LNLAL-01 by HPTLC	87
4.10	Validation parameters for quantification of $\beta$ -sitosterol by HPTLC	90
4.11	Validation parameters for quantification of LNLAL-01 by HPLC	91
4.12	% inhibition by various fractions of LN by DPPH method and IC <sub>50</sub> values	94
4.13	% inhibition by various fractions of LN by FeCl <sub>3</sub> method and IC <sub>50</sub> values	95
4.14	% inhibition by various fractions of LN by phosphomolybdenum method and IC <sub>50</sub> values	96
4.15	IC <sub>50</sub> of active fractions from LN	99
4.16	% inhibition of different fractions in LOX inhibition assay	103
4.17	IC <sub>50</sub> of active fractions from <i>L. nepetaefolia</i>	107
4.18	Difference in paw volume ( $\Delta V$ mL) of control and treated rats	113
4.19	Difference in paw volume ( $\Delta V$ mL) of control and treated rats	114
4.20	Pre convulsion time of various groups	115
4.21	Proximate analysis of whole plant of <i>O. corniculata</i>	120
4.22	Successive extracts of whole plant of <i>O. corniculata</i>	121
4.23	Phytoconstituents present in successive extracts of <i>O. corniculata</i>	121

Table no.	Legend	Page no.
4.24	TLC profile of successive extracts of whole plant of <i>O. corniculata</i>	122
4.25	Secondary metabolites in different extracts of <i>O. corniculata</i>	123
4.26	Validation parameters of quantification of OC-01 by HPTLC	129
4.27	Validation parameter for the quantification of OC-01 by HPLC	131
4.28	IC <sub>50</sub> of OC fractions by three methods	134
4.29	Serum transaminases of different group of rats	136
4.30	CPK-MB and LDH levels in serum of rats	137
4.31	Antioxidant milieu and MDA levels in rat hearts	138